Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Buy now fake rolex


Double Covid blow for AZ

Posted 17 June 2021 PM 

A double strike for AstraZeneca after federal government advisers put the squeeze on the number of Australians who should have the jab - barely 24 hours after the company announced its Covid antibody combo had failed a phase 3 clinical trial.

New advice from the Australian Technical Advisory Group on Immunisation (ATAGI) has recommended the AstraZeneca vaccine be confined to those aged 60 plus, after the death of a 52-year-old NSW woman from a "severe form" of blood clotting in the brain, was announced last week.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
Pitfalls may plague NMP review
With an election in play, will it arrive too late?
Approvals Action
First copy of Halaven ticked
Along with other generics of already PBS-listed drugs